---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-000009"
form_type: "8-K"
ticker: "CPMV"
cik: "0000836564"
company_name: "Mosaic ImmunoEngineering Inc."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T19:18:03.353396+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Mosaic ImmunoEngineering extends Oncotelic acquisition term sheet to June 30, 2025

## Summary
- Binding term sheet for acquisition of Oncotelic's necroptosis cancer therapies and AI tech extended to June 30, 2025.
- Original deal: $15M stock issuance at closing plus up to $15M milestone shares.
- Extension allows more time for due diligence and drafting definitive agreements; no guarantee a deal will close.
- Parties continue negotiating; prior expiration was December 31, 2024.

## SEC filing metadata
- accession: 0001683168-25-000009
- form_type: 8-K
- ticker: CPMV
- cik: 0000836564
- company_name: Mosaic ImmunoEngineering Inc.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/836564/000168316825000009/0001683168-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/836564/000168316825000009/mosaic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-000009
- JSON: https://secwatch.observer/filing/0001683168-25-000009.json
- Plain text: https://secwatch.observer/filing/0001683168-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.